INVESTIGATION OF PROLIFERATIVE ACTIVITY OF CELLS OF RADIOIODINE RESISTANT THYROID PAPILLARY CANCER METASTASES
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-2-2019-g.7134Keywords:
fine-needle-aspiration puncture biopsy, papillary thyroid carcinoma, proliferative activity, punctate, radioiodine-resistant metastases, Кі-67Abstract
Objective: comparative studies of the expression of marker of сеlls’ proliferative activity (the antigen of Ki-67) in punctates of radioiodine-resistant (RIRM), radioiodine-sensitive metastases (RISM) and the general group of papillary thyroid carcinoma metastases. Object and methods: cytomorphological and imunocytochemical studies using monoclonal antibody against antigen Ki-67 (МІВ-1) were perfomed on the material of fine needle aspiration biopsy of papillary thyroid carcinomas metastases: 29 — were detected before surgery, 38 — were detected in the postoperative period (27 — RIRM, 11 — RISM); as well as on punctates of 4 medullary carcinomas, 10 papillary carcinomas (PC) and 10 nodular goiters. Results: the technique of immunocytochemical determination of cells proliferative activity marker in punctates, painted according to the Romanovsky method, was worked out. The highest percentage of Ki-67-positive cells was observed in punctates of medullary carcinoma (7–10%), the diffuse-sclerosing variant of PC (7–12%) and PC associated with autoimmune thyroiditis (6–35%). Based on the results of the Mann — Whitney criterion, significant difference between RIRM and the general population of PC metastases, and between RIRM and RISM of papillary thyroid carcinoma wasn’t detected. There was a tendency to increase the content of Ki-67-positive cells in punctates of repeated RIRM of recurrent PC. Conclusion: the absence of statistically significant difference in expression of Ki-67 between the studied groups of papillary thyroid carcinoma metastases was demonstrated. This indicates the independence of radioiodine accumulation capacity from the intensity of the proliferative processes of thyrocytes of papillary metastases. There is a tendency to increase the content of Ki-67-positive cells in punctates of repeated RIRM of recurrent PC.
References
Haugen BR, Alexander EK, Bible KC, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26 (1): 1–133.
Pacini F, Itо Y, Luster M. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab 2012; 7 (5): 541–4.
Deandreis D, Ghuzlan A, Leboulleux S, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011; 1 (18): 159–69.
Castro MR, Bergert ER, Goellner JR, et al. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 2001; 86 (11): 5627–32.
Min JJ, Chung JK, Lee Y, et al. Relationship between expression of the sodium/iodide symporter and (131)I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001; 28 (5): 639–45.
Xing M, Westra W, Tufano R, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90 (12): 6373.
Zelinskaya A. The possibility of cytological diagnostics in preoperative prognosis of tumor behavior and the choice of adequate therapy. Endocrinol 2018; 23 (1): 47–53
Bozhok YuM‚ Tavokina LV, Epstein EV. The new things in diagnostic of thyroid cancer. Optimal combination of morphological and immunocytochemistry research methods of punctious materials. Medicinal announcer (USA) 1996; 138 (1): 40–3.
Yarmonenko SP. Radiobiology of Humans and Animals. M: Vysshaya shkola 1988. 424 p. (in Russian).
Schlüter C, Duchrow M, Wohlenberg C, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993; 123 (3): 513–22.
Luporsi E, André F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132 (3): 895–915.
Berney D, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009; 100 (6): 888–93.
Miyauchi A, Kudo T, Hirokawa M, et al. Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J 2013; 2 (1): 57–64.
Ito Y, Miyauchi A, Kakudo K, et al. Prognostic significance of Ki-67 labeling index in papillary thyroid carcinoma. World J Surg 2010; 34 (12): 3015–21.
